Peter Wilver, Stephen Williamson
Thermo Fisher Scientific said that CFO Peter Wilver will retire, effective March 31, 2016. The firm's board of directors has named Stephen Williamson, currently VP of financial operations, to become the new CFO, effective Aug. 1, 2015. Wilver joined the firm in 2004 as CFO, and during his tenure the company's market cap grew from $5 billion to around $50 billion today, President and CEO Marc Casper noted in a statement.
Williamson joined Thermo Fisher in 2001 as VP of European financial operations, based in theUK, and subsequently served as the finance lead for the Informatics and Services, and the Environmental Instruments businesses. He was named VP of finance for Analytical Technologies in 2006, and two years later became VP of financial operations for the company.
Mary Lopez has joined Nuclea Biotechnologies as chief operating officer. Her main responsibility will be commercializing the company's US Food and Drug Administration-approved and CLIA-based tests. Lopez was most recently the director of Thermo Fisher Scientific's Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center. Prior to joining Thermo Fisher, she was strategic collaborations leader and analytical proteomics business leader at PerkinElmer Life and Analytical Sciences, and executive vice president of proteomics research and development at Proteome Systems.
Pathway Genomics has named Anja Kammesheidt its vice president of research and development. She joins the firm from Agendia where she worked on genomics-based personalized diagnostics and directed translational science projects. Prior to that, she served as chief scientific officer at Ambry Genetics for 10 years.
Kammesheidt received her bachelor and doctoral degrees in biological sciences from the University of California, Irvine, with a focus on molecular neurobiology. After completing her postdoctoral training at the University of California, San Diego, she joined Purdue Pharma as a research scientist focused on neuropathic pain targets.
Former Affymetrix CFO Tim Barabe has been appointed to the board of Vigilant Biosciences. He retired as CFO of Affy in 2013. Before joining Affy, he was senior vice president and CFO of Human Genome Sciences from 2006 to 2010 and was CFO of Regent Medical from 2004 to 2006. Barabe also serves on the board of Opexa Therapeutics and ArQule.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.